Vanda Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 203

Market Cap: $311.8M

Website

Introduction: Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The ...

Clinical Trials

Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant

Phase 3

Recruiting

Conditions: Sleep Wake Disorders
Sleep Disorders, Circadian Rhythm
Chronobiology Disorders
Gene Mutations and Other Alterations Nec

Interventions: Drug: Placebo
Drug: Tasimelteon

First Posted Date: 2024-11-22

Last Posted Date: 2024-11-22

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT06701396

Locations: 🇹🇷
Vanda Investigational Site, Çankaya, Ankara, Turkey

Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions

Phase 1

Not yet recruiting

Conditions: Schizophrenia
Bipolar I Disorder

Interventions: Drug: VHX-896 and iloperidone
Drug: Iloperidone and VHX-896

First Posted Date: 2024-07-10

Last Posted Date: 2024-07-10

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT06494397

Locations: 🇺🇸
Vanda Investigational Site, Marlton, New Jersey, United States

Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Tasimelteon
Drug: Active Control
Drug: Active Control Placebo
Drug: Tasimelteon Placebo

First Posted Date: 2024-03-21

Last Posted Date: 2024-03-21

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT06323655

Locations: 🇨🇦
Vanda Investigational Site, Laval, Quebec, Canada

A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

Phase 2

Recruiting

Conditions: Dry Eye

Interventions: Drug: Placebo
Drug: VSJ-110

First Posted Date: 2024-03-06

Last Posted Date: 2024-03-06

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT06296966

Locations: 🇺🇸
Vanda Investigational Site, Andover, Massachusetts, United States

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

Phase 3

Recruiting

Conditions: Motion Sickness

Interventions: Drug: Tradipitant

First Posted Date: 2023-11-18

Last Posted Date: 2024-03-21

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 500

Registration Number: NCT06138613

Locations: 🇺🇸
Santa Monica Clinical Trials, Santa Monica, California, United States

Motion Serifos: a Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

Phase 3

Completed

Conditions: Motion Sickness

Interventions: Drug: Tradipitant
Drug: Placebo

First Posted Date: 2023-06-15

Last Posted Date: 2024-11-22

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 316

Registration Number: NCT05903924

Locations: 🇺🇸
Pacific Research Partners, San Diego, California, United States
🇺🇸
Lumos Clinical Research, San Jose, California, United States
🇺🇸
Santa Monica Clinical Trials, Santa Monica, California, United States

and more 2 locations

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

Phase 4

Recruiting

Conditions: Schizophrenia
Bipolar I Disorder

Interventions: Drug: Iloperidone

First Posted Date: 2022-12-13

Last Posted Date: 2024-03-20

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT05648591

Locations: 🇺🇸
Vanda Investigational Site, Everett, Washington, United States

Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tasimelteon Oral Capsule
Drug: Tasimelteon Oral Suspension

First Posted Date: 2022-10-07

Last Posted Date: 2024-03-21

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT05572281

Locations: 🇺🇸
Vanda Investigational Site, Springfield, Missouri, United States

Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances

Phase 3

Recruiting

Conditions: Autism Spectrum Disorder
Sleep Disorder
Neurological Disorder
Sleep Disturbance

Interventions: Drug: Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension

First Posted Date: 2022-05-05

Last Posted Date: 2024-03-21

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT05361707

Locations: 🇺🇸
Vanda Investigational Site, Staten Island, New York, United States

A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis

Phase 2

Withdrawn

Conditions: Parkinson Disease Psychosis

Interventions: Drug: Iloperidone

First Posted Date: 2022-04-25

Last Posted Date: 2024-03-21

Lead Sponsor: Vanda Pharmaceuticals

Registration Number: NCT05344365

Locations: 🇺🇸
Vanda Investigational Site, Saint Petersburg, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy